These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 30020421)

  • 1. Repurposing an Old Drug for a New Epidemic: Ursodeoxycholic Acid to Prevent Recurrent Clostridioides difficile Infection.
    Webb BJ; Brunner A; Lewis J; Ford CD; Lopansri BK
    Clin Infect Dis; 2019 Jan; 68(3):498-500. PubMed ID: 30020421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ursodeoxycholic Acid Inhibits Clostridium difficile Spore Germination and Vegetative Growth, and Prevents the Recurrence of Ileal Pouchitis Associated With the Infection.
    Weingarden AR; Chen C; Zhang N; Graiziger CT; Dosa PI; Steer CJ; Shaughnessy MK; Johnson JR; Sadowsky MJ; Khoruts A
    J Clin Gastroenterol; 2016 Sep; 50(8):624-30. PubMed ID: 26485102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ursodeoxycholic acid after common bile duct stones removal for prevention of recurrence: A systematic review and meta-analysis of randomized controlled trials.
    Chen X; Yan XR; Zhang LP
    Medicine (Baltimore); 2018 Nov; 97(45):e13086. PubMed ID: 30407311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.
    Gerding DN; Kelly CP; Rahav G; Lee C; Dubberke ER; Kumar PN; Yacyshyn B; Kao D; Eves K; Ellison MC; Hanson ME; Guris D; Dorr MB
    Clin Infect Dis; 2018 Aug; 67(5):649-656. PubMed ID: 29538686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study.
    Assis DN; Abdelghany O; Cai SY; Gossard AA; Eaton JE; Keach JC; Deng Y; Setchell KD; Ciarleglio M; Lindor KD; Boyer JL
    J Clin Gastroenterol; 2017 Feb; 51(2):e11-e16. PubMed ID: 27428727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid.
    Levy C; Peter JA; Nelson DR; Keach J; Petz J; Cabrera R; Clark V; Firpi RJ; Morelli G; Soldevila-Pico C; Lindor K
    Aliment Pharmacol Ther; 2011 Jan; 33(2):235-42. PubMed ID: 21083674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healthcare burden of recurrent Clostridioides difficile infection in Japan: A retrospective database study.
    Kunishima H; Ito K; Laurent T; Abe M
    J Infect Chemother; 2018 Nov; 24(11):892-901. PubMed ID: 30190105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of ursodeoxycholic acid (UDCA) in the treatment of chronic alcoholic hepatitis].
    Preobrazhenskiĭ VN; Taianovskiĭ VIu
    Klin Med (Mosk); 1998; 76(5):26-8. PubMed ID: 9644931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent
    Song JH; Kim YS
    Gut Liver; 2019 Jan; 13(1):16-24. PubMed ID: 30400734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioavailability of a controlled release formulation of ursodeoxycholic acid in man.
    Alvisi V; Gasparetto A; Dentale A; Heras H; Felletti-Spadazzi A; D'Ambrosi A
    Drugs Exp Clin Res; 1996; 22(1):29-33. PubMed ID: 8839635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Clostridioides difficile: New uses for old drugs.
    Chen J; Li Y; Wang S; Zhang H; Du Y; Wu Q; Wang H
    Drug Discov Today; 2022 Jul; 27(7):1862-1873. PubMed ID: 35390545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.
    Wunsch E; Trottier J; Milkiewicz M; Raszeja-Wyszomirska J; Hirschfield GM; Barbier O; Milkiewicz P
    Hepatology; 2014 Sep; 60(3):931-40. PubMed ID: 24519384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence.
    Bosch A; Dumortier J; Maucort-Boulch D; Scoazec JY; Wendum D; Conti F; Morard I; Rubbia-Brandt L; Terris B; Radenne S; Abenavoli L; Poupon R; Chazouillères O; Calmus Y; Boillot O; Giostra E; Corpechot C
    J Hepatol; 2015 Dec; 63(6):1449-58. PubMed ID: 26282232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent developments in the management of recurrent Clostridioides difficile infection.
    Mendo-Lopez R; Villafuerte-Gálvez J; White N; Mahoney MV; Kelly CP; Alonso CD
    Anaerobe; 2020 Apr; 62():102108. PubMed ID: 31606481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: 12-Month Observational Data From the Randomized Phase III Trial, MODIFY II.
    Goldstein EJC; Citron DM; Gerding DN; Wilcox MH; Gabryelski L; Pedley A; Zeng Z; Dorr MB
    Clin Infect Dis; 2020 Aug; 71(4):1102-1105. PubMed ID: 31883370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Characteristics of a new controlled release formulation of ursodesoxycholic acid].
    Carli F; Brambilla A; Di Rella M; Frattini C; Brandt A
    Boll Chim Farm; 1996 Jan; 135(1):12-4. PubMed ID: 9004735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia.
    Lindström L; Boberg KM; Wikman O; Friis-Liby I; Hultcrantz R; Prytz H; Sandberg-Gertzén H; Sangfelt P; Rydning A; Folvik G; Gangsøy-Kristiansen M; Danielsson A; Bergquist A
    Aliment Pharmacol Ther; 2012 Feb; 35(4):451-7. PubMed ID: 22221173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of prevention of biliary stent occlusion by ursodeoxycholic acid plus norfloxacin.
    Tarnasky PR; Cotton PB
    Gastrointest Endosc; 1995 Jul; 42(1):103-4. PubMed ID: 7557168
    [No Abstract]   [Full Text] [Related]  

  • 19. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response.
    van de Meeberg PC; Wolfhagen FH; Van Berge-Henegouwen GP; Salemans JM; Tangerman A; van Buuren HR; van Hattum J; van Erpecum KJ
    J Hepatol; 1996 Dec; 25(6):887-94. PubMed ID: 9007717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimum dose of ursodeoxycholic acid in primary biliary cirrhosis.
    Verma A; Jazrawi RP; Ahmed HA; Davis T; Bland JM; Benson M; Orchard RT; Theodossi A; Maxwell JD; Northfield TC
    Eur J Gastroenterol Hepatol; 1999 Oct; 11(10):1069-76. PubMed ID: 10524634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.